Citicoline for Mood in Healthy Adults
This study is looking at how a dietary supplement called citicoline affects mood in healthy adults. Researchers want to see if taking citicoline can improve your mood compared to taking a placebo (an inactive substance). You might be able to join if you are a healthy man or woman between 21 and 65 years old, with a BMI between 18.5 and 32.0, and weigh at least 110 pounds. The main goal is to measure changes in your overall mood after 4 weeks using a special questionnaire. The current status of this study is unclear.
- Study design
- This is a 4-week, randomized, double-blind, placebo-controlled study. It plans to include 90 healthy men and women.
- What's involved
- You would take either citicoline or a placebo orally for 4 weeks. Cognitive assessments will be performed to measure your mood.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your mood will be measured at 4 weeks after starting the intervention.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07089238
Evaluate the Effects of Citicoline on Mood in Healthy Adults
Recruiting
NAAges 21–65InterventionalHealth servicesKirin Holdings Company, Limited
~90 participants
Updated 2025-09-02 on ClinicalTrials.gov
What's tested:CiticolinePlacebo
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Total Mood Disturbance (TMD) score on the Profile of Mood States second eddition-Adult short (POMS2)
Measured over 4 weeks
Conditions
Where it's being run
1 sites across 1 statesOhio1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Provide voluntary signed and dated informed consent.
Be in good health and able to participate as determined by medical history and routine blood chemistries.
Biological men and women between 21 and 65 years of age (inclusive).
Body Mass Index of 18.5-32.0 (inclusive).
Body weight of at least 110 pounds.
Participant is experiencing moderate levels of mood disturbance during screening.
Normotensive (seated, resting systolic blood pressure \<140 mm Hg and diastolic blood pressure \< 90 mm Hg.
Normal supine, resting heart rate (\<90 per minute).
Agrees to maintain their existing dietary and physical activity patterns throughout the study period.
Participants agree to maintain their usual caffeine consumption habits, given that they do not exceed the maximum intake per day (400mg/day or 3-4 cups of coffee per day).
If a dietary supplement was initiated within the past month, the participant is willing to discontinue supplement use followed by a 2-week washout prior to participation in the study.
Willing to duplicate their previous 24-hour diet, refrain from caffeine for 24 hours, refrain from alcohol and exercise for 24 hours prior to each trial, and fast for 10 hours prior to each visit.
Exclusion
QIDS (Quick Inventory of Depressive Symptomology) score \> 16.
Women who are pregnant, lactating, or planning to become pregnant during the study. Women must have a negative pregnancy test at screening.
Women with a PSST (Premenstrual Symptoms Screening Tool) score ≥30
Current smokers or cessation within 3 months prior to screening.
Alcohol consumption (\>2 standard alcoholic drinks/day or \>10 drinks/week) or drug abuse/dependence.
Current use of any nootropic dietary supplements (e.g., GABA, Ashwaghanda, St. John's Wort, Ginkgo biloba, L-theanine, choline, Lion's mane, creatine, etc.) or medications (e.g., piracetam, Adderall, modafinil, etc.) that may confound the study or its endpoints.
Medical history of hepatorenal, musculoskeletal, autoimmune, or neurologic disease.
Individuals who have been diagnosed with digestive, liver, renal, cardiovascular, or other metabolic diseases.
Other known gastrointestinal or metabolic diseases that might impact nutrient absorption, distribution, metabolism, or excretion (e.g., intestinal malabsorption, electrolyte abnormalities, diabetes, thyroid disease, adrenal disease, hypogonadism, short bowel syndrome, diarrheal illnesses, history of colon resection, gastric ulcer, reflux disease, gastroparesis, Inborn-Errors-of-Metabolism, etc.).
Chronic medically diagnosed inflammatory condition or disease (e.g., rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.).
Medical history of a cognitive (i.e., ADD/ADHD) or psychiatric disorder, or brain-related medical conditions (e.g., TBI, ADHD).
Currently using medications to treat anxiety or depression.
Have an irregular sleep pattern (i.e. shift workers) or inadequate sleep schedule (i.e., less than 6 hours per night).
Known sensitivity, allergy, or intolerability to any ingredient in the test products.
Participants who report a clinically significant illness within the last 30 days.
Individuals who are cognitively impaired and/or who are unable to give informed consent.
Any other diseases or conditions that, in the opinion of the Principal Investigator, could confound the primary endpoint or place the subject at increased risk of harm if they were to participate.
What this trial measures
- Total Mood Disturbance (TMD) score on the Profile of Mood States second eddition-Adult short (POMS2)4 weeks
To evaluate the effect of the Test Product (TP) on TMD on the POMS2 compared to a placebo